Laboratory Co. of America Holdings (NYSE:LH) Shares Acquired by Choreo LLC

Choreo LLC grew its position in Laboratory Co. of America Holdings (NYSE:LH - Free Report) by 103.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,099 shares of the medical research company's stock after acquiring an additional 2,596 shares during the quarter. Choreo LLC's holdings in Laboratory Co. of America were worth $1,167,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in LH. OneDigital Investment Advisors LLC grew its holdings in shares of Laboratory Co. of America by 115.7% in the third quarter. OneDigital Investment Advisors LLC now owns 6,088 shares of the medical research company's stock worth $1,361,000 after purchasing an additional 3,265 shares during the last quarter. Alexander Randolph Advisory Inc. bought a new position in shares of Laboratory Co. of America in the third quarter worth about $955,000. Wealthcare Advisory Partners LLC grew its holdings in shares of Laboratory Co. of America by 23.9% in the fourth quarter. Wealthcare Advisory Partners LLC now owns 2,543 shares of the medical research company's stock worth $583,000 after purchasing an additional 490 shares during the last quarter. Mutual of America Capital Management LLC bought a new position in shares of Laboratory Co. of America in the third quarter worth about $2,316,000. Finally, Barclays PLC grew its holdings in shares of Laboratory Co. of America by 11.8% in the third quarter. Barclays PLC now owns 620,721 shares of the medical research company's stock worth $138,718,000 after purchasing an additional 65,356 shares during the last quarter. Hedge funds and other institutional investors own 95.94% of the company's stock.

Insider Activity at Laboratory Co. of America

In other Laboratory Co. of America news, EVP Der Vaart Sandra D. Van sold 1,000 shares of the firm's stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $239.42, for a total transaction of $239,420.00. Following the completion of the transaction, the executive vice president now directly owns 2,670 shares of the company's stock, valued at approximately $639,251.40. This trade represents a 27.25 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CMO Amy B. Summy sold 3,672 shares of the firm's stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $238.91, for a total transaction of $877,277.52. Following the transaction, the chief marketing officer now directly owns 4,318 shares of the company's stock, valued at $1,031,613.38. This represents a 45.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,383 shares of company stock valued at $4,408,373 in the last three months. 0.85% of the stock is owned by insiders.

Laboratory Co. of America Stock Down 1.7 %

Shares of NYSE:LH traded down $4.09 during trading on Wednesday, reaching $241.05. The stock had a trading volume of 931,377 shares, compared to its average volume of 613,788. Laboratory Co. of America Holdings has a one year low of $191.97 and a one year high of $258.59. The company has a market capitalization of $20.16 billion, a P/E ratio of 27.33, a PEG ratio of 1.84 and a beta of 1.07. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.67. The firm's 50-day simple moving average is $236.85 and its 200 day simple moving average is $230.48.

Laboratory Co. of America (NYSE:LH - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $3.45 earnings per share for the quarter, beating analysts' consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. As a group, research analysts expect that Laboratory Co. of America Holdings will post 15.96 EPS for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Investors of record on Thursday, February 27th will be given a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 1.19%. The ex-dividend date is Thursday, February 27th. Laboratory Co. of America's payout ratio is currently 32.65%.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on LH. StockNews.com upgraded shares of Laboratory Co. of America from a "hold" rating to a "buy" rating in a report on Friday, February 7th. UBS Group cut their price target on shares of Laboratory Co. of America from $293.00 to $286.00 and set a "buy" rating on the stock in a report on Tuesday, January 28th. Evercore ISI upgraded shares of Laboratory Co. of America from an "in-line" rating to an "outperform" rating and upped their price target for the stock from $260.00 to $265.00 in a report on Tuesday, January 7th. Robert W. Baird increased their target price on shares of Laboratory Co. of America from $282.00 to $289.00 and gave the stock an "outperform" rating in a report on Friday, October 25th. Finally, Hsbc Global Res upgraded shares of Laboratory Co. of America from a "hold" rating to a "strong-buy" rating in a report on Wednesday, October 30th. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $265.31.

Laboratory Co. of America Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.